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Abstract 
Without a complete published description of interventions, clinicians and patients cannot reliably 
implement interventions that are shown to be useful and other researchers cannot replicate or 
build on research findings. However the quality of intervention description in publications is 
remarkably poor. To improve the completeness of reporting, and ultimately the replicability, of 
interventions, an international group of experts and stakeholders developed the Template for 
Intervention Description and Replication (TIDieR) checklist and guide. The process involved a 
literature review for relevant checklists and research, a Delphi survey of an international panel of 
experts to guide item selection, and a face-to-face panel meeting. The resultant 12-item TIDieR 
checklist [brief name, why, what (materials), what (procedure), who provided, how, where, when 
and how much, tailoring, modifications, how well (planned), how well (actual)] is an extension 
of the CONSORT 2010 Statement (Item 5) and the SPIRIT 2013 Statement (Item 11). While the 
emphasis of the checklist is on trials, the guidance is intended to apply across all evaluative study 
designs. This paper presents the TIDieR checklist and guide, with an explanation and elaboration 
for each item, and examples of good reporting. The TIDieR checklist and guide should improve 
the reporting of interventions and make it easier for authors to structure accounts of their 
interventions, reviewers and editors to assess the descriptions, and readers to use the information. 
Introduction 
The evaluation of interventions is a major research activity, yet the quality of intervention 
description in publications remains remarkably poor. Without a complete published description 
of the intervention, other researchers cannot replicate or build on research findings and for 
effective interventions, clinicians, patients, and other decision makers are left unclear about how 
to reliably implement the intervention. Intervention description involves more than providing a 
label or the ingredients list. Key features, including duration, dose or intensity, mode of delivery, 
essential processes, and monitoring, can all influence efficacy and replicability, but are often 
missing or poorly described. For complex interventions, this detail is needed for each component 
of the intervention. For example, a recent analysis found that only 11% of 262 trials of cancer 
chemotherapy provided complete details of the trial treatments.1 The most frequently missing 
elements were dose-adjustment and pre-medications, but 16% of trials omitted even the route of 
drug administration. The completeness of intervention description is often worse for non-
pharmacological interventions: one analysis of trials and reviews found that 67% of drug 
intervention descriptions were adequate compared with only 29% of non-pharmacological 
interventions.2 A recent study of 137 interventions, from 133 trials of non-drug interventions, 
found that only 39% of interventions were described adequately in the primary paper or any 
references, appendices or websites.3 This increased, albeit to only 59%, by contacting authors for 
additional information– a task almost no clinicians and few researchers have time to undertake. 
The Consolidated Standards of Reporting Trials (CONSORT) 2010 Statement4 currently 
suggests in Item 5 that authors should report on “The interventions for each group with sufficient 
details to allow replication, including how and when they were actually administered”. This is 
appropriate advice, but further guidance appears needed: despite endorsement of the CONSORT 
Statement by many journals, intervention reporting is deficient. The problem partly arises from 
lack of awareness among authors about what comprises a good description, and lack of attention 
by peer reviewers and editors.5   
A small number of CONSORT extension statements contain expanded guidance about 
describing interventions, such as non-pharmacological interventions 6 and specific intervention 
categories, such as acupuncture and herbal interventions. 7,8 The guidance for content of trial 
protocols, SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials), 
provides some recommendations for describing interventions in protocols.9 More generic and 
comprehensive guidance is needed along with robust ways to implement such guidance. We 
developed an extension of Item 5 of the CONSORT 2010 Statement and Item 11 of the SPIRIT 
2013 Statement, in the form of a checklist and guidance entitled TIDieR (Template for 
Intervention Description and Replication), with the objective of improving the completeness of 
reporting, and ultimately the replicability, of interventions. This article describes the methods 
used to develop and obtain consensus for this checklist, and for each item, provides an 
explanation, elaboration, and examples of good reporting. While the emphasis of the checklist is 
on trials, the guidance is intended to apply across all evaluative study designs, such as trials, 
case-control studies, and cohort studies.  
Methods for development of the TIDieR Checklist and Guide 
Development of the checklist followed the methodological framework for developing reporting 
guidelines suggested by the EQUATOR Network.10 In collaboration with the CONSORT 
steering group, we established a TIDieR steering committee (PPG, TCH, IB, RM, RP). The 
committee generated a list of 34 potential items from relevant CONSORT checklists and 
checklists for reporting discipline-specific or particular categories of interventions. The group 
also reviewed other sources of guidance on intervention reporting identified from a thorough 
search of the literature, followed by a forward and backward citation search (see web appendix 
1). 
We then used a two-round modified Delphi consensus survey method 11 involving a broad range 
of expertise and stakeholders. In the first round, each of the 34 items generated by the steering 
committee was rated by survey participants as ‘omit’, ‘possible’, ‘desirable’ or ‘essential’ to 
include in the final checklist. From the first round, some items were reworded and combined, and 
then the ranked items were divided into three groups for the second round. The first group 
contained 13 items with the highest rankings (rated as ‘essential’ by ≥70% participants or 
‘essential or desirable’ by ≥85%), and participants were advised that these would be included in 
the checklist unless strong objection to their inclusion was received in the second round. The 
second group contained 13 items with moderate rankings (‘essential or desirable’ by ≥65%); 
participants were asked to rate each of these, again as ‘omit’, ‘possible’, ‘desirable’ or ‘essential’. 
The third group contained 3 items with low rankings, and participants were advised that these 
items would be removed unless strong objection to their omission was received in the second 
round. In both rounds, participants could also suggest additional items, comment on item 
wording, or provide general comments. 
Delphi participants (n=125) were authors of research on describing interventions, clinicians, 
authors of existing reporting guidelines, clinical trialists, methodologists or statisticians with 
expertise in clinical trials, and journal editors (see web appendix  2). They were invited by email 
to complete the two rounds of the web-based survey. The response rate was 72% (n=90) for the 
first round. Only those who completed round one and were willing to participate in round two 
were invited to participate in round two. The response rate for round two was 86% (74 of 86 
invited). 
After the two Delphi rounds, 13 items were included in the draft checklist and 13 moderately-
rated items were retained for further discussion at the in-person meeting. The results of the 
Delphi survey were reported at a two-day consensus meeting on 27-28 March 2013, in Oxford, 
UK. Thirteen invited experts, representing a range of health disciplines (see author list), and with 
trial, methodological, and/or reporting guideline development expertise, attended and are all 
authors of this paper. The meeting began with a review of the intervention reporting literature, 
followed by a report of the Delphi process, the draft checklist of 13 items, and rankings of and 
comments about the additional 13 moderately-rated items. Meeting participants discussed the 
proposed items and agreed which should be included and the wording of each item.  
Following the meeting, the checklist was distributed to the participants to ensure it reflected the 
decisions made and this explanation and elaboration document was drafted. This was then 
piloted with 26 researchers who were authoring papers of intervention studies and minor 
clarifications were made in the elaboration of some items.   
Scope of the TIDieR Checklist and Guide for Describing Interventions  
The overarching purpose of the TIDieR checklist is to prompt authors to describe interventions 
in sufficient detail to allow their replication. The checklist contains the minimum recommended 
items for describing an intervention. Authors should provide additional information where they 
feel it necessary for the replication of an intervention.  
Most TIDieR items are relevant for the majority of interventions and applicable to even 
apparently simple drug interventions, which are sometimes poorly described.2 Considering the 
elements of an evaluation of an intervention - the Population, Intervention, Comparison, 
Outcome (“PICO”) - TIDieR can be seen as a guide for reporting the Intervention, and 
Comparison (and co-interventions, where relevant), elements of a study. Other elements (such as 
Population, Outcomes) and methodological features are covered by CONSORT 2010 or SPIRIT 
2013 items for randomised trials, and by other checklists (e.g. STROBE statement12) for alternate 
study designs. They have not been duplicated as part of the TIDieR checklist.  
The order in which items are presented in the checklist does not necessarily reflect the order in 
which information should be presented. It may also be possible to combine a number of items 
from the checklist into one sentence. For example, information about what materials (Item 3) and 
what processes (Item 4) may be combined (example 3c).  
We emphasise that our definition of ‘intervention’ extends to describing the intervention 
received by the comparison group/s in a study. Control interventions and co-interventions are 
often particularly poorly described; “usual care” is not a sufficient description. When a 
controlled study is reported, authors should describe what control group participants received 
with the same level of detail, used to describe the intervention group, within the limits of 
feasibility. Full understanding of the comparison group care may help explain the observed 
efficacy of an intervention, with greater apparent effect sizes being potentially found when 
control group care is minimal.13 Describing the care that each group received will usually require 
replicating the checklist for each group in a study.  
As well as describing which interventions (or control conditions) were delivered to different 
groups, authors should also explain legitimate variants of the intervention. Authors may find it 
helpful to locate their trial on the pragmatic-explanatory continuum.14 If, for example in a 
pragmatic trial, authors expect there to be variants in aspects of the intervention (for instance, in 
the ‘usual care’ group across various centres), those variants should be described under the 
appropriate checklist items.   
We recognise that limitations (such as format and length), for journals that are only paper-based 
may sometimes preclude inclusion of all intervention information in the primary paper (that is, 
the paper that is reporting the main results of the intervention evaluation). The information that is 
prompted by the TIDieR checklist might therefore be reported in locations beyond the primary 
paper itself, including online supplementary material linked to the primary paper, a published 
protocol and/or other published papers, or a website. Authors should specify the location of 
additional detail in the primary paper (for example, “online appendix 2 for the training manual”, 
“available at www...”, or “details are in our published protocol”). When websites provide further 
details, URLs that are designed to remain stable over time are essential.   
The TIDieR Checklist Explanation and Elaboration 
The checklist is shown in Table 1. It is also available for download as a Word document (web 
appendix 3) and PDF (web appendix 4) and also at the EQUATOR Network website 
(www.equator-network.org/reporting-guidelines/tidier/). An explanation for each item is given 
below, along with examples of good reporting. Citations for the examples are in Table 2. 
Item 1. BRIEF NAME: Provide the name or a phrase that describes the intervention. 
Examples: 
1a. “single …dose of dexamethasone” 
1b. “TREAD (TREAtment of Depression with physical activity) study” 
1c. “Internet-based, nurse-led vascular risk factor management programme promoting self-
management” 
Explanation: Precision in the name, or brief description, of an intervention enables easy 
identification of the type of intervention and facilitates linkage to other reports on the same 
intervention. Give the intervention name (examples 1a, 1b), explaining any abbreviations or 
acronyms in full (example 1b), or a short (1 or 2 line) statement of the intervention without 
elaboration (example 1c).   
Item 2. WHY: Describe any rationale, theory, or goal of the elements essential to the 
intervention. 
Examples:  
2a. “Dexamethasone (10 mg) or placebo was administered 15 to 20 minutes before or with 
the first dose of antibiotic… Studies in animals have shown that bacterial lysis, induced by 
treatment with antibiotics, leads to inflammation in the subarachnoid space, which may 
contribute to an unfavourable outcome [references]. These studies also show that adjuvant 
treatment with anti-inflammatory agents, such as dexamethasone, reduces both 
cerebrospinal fluid inflammation and neurologic sequelae [references].” 
2b. “Self-management of oral anticoagulant therapy may result in a more individualised 
approach, increased patient responsibility, and enhanced compliance, which may lead to 
improvement in the regulation of anticoagulation.” 
2c. “The TPB [Theory of Planned Behaviour] informed the hypothesised mediators of 
intention and physical activity that were targeted in the intervention program: instrumental 
and affective attitude, subjective norm and perceived behavioural control.  
2d. “We chose a 5 degree wedge because greater wedging is less likely to be tolerated by 
the wearer [reference] and is difficult to accommodate within a normal shoe.”  
Explanation: Inclusion of the rationale, theory, or goals that underpin an intervention, or the 
components of a complex intervention,15 can help others to know which elements are essential, 
rather than optional or incidental. For example, the colour of capsules used in a pharmacological 
intervention is likely to be an incidental, not essential, contributor to the intervention’s efficacy 
and hence reporting of this is not necessary. In some literature, the term ‘active ingredient’ is 
used and refers to the components within an intervention that can be specifically linked to its 
effect on outcomes such that, if they were omitted, the intervention would be ineffective.16 The 
known or supposed mechanism of action of the active component/s of the intervention should be 
described.  
Example 2a illustrates the rationale for treating bacterial meningitis with dexamethasone in 
addition to an antibiotic. Behaviour change and implementation interventions may require 
different forms of description, but the basic principles are the same. It may, alongside an account 
of the components of the intervention, be appropriate also to describe the intervention in terms of 
its theoretical basis, including its hypothesised mechanisms of action (examples 2b, 2c).17–19 The 
rationale behind an important element of an intervention may sometimes be pragmatic and relate 
to acceptability of the intervention by participants (example 2d).  
Item 3. WHAT (materials): Describe any physical or informational materials used in the 
intervention, including those provided to participants or used in intervention delivery or in 
training of intervention providers. Provide information on where the materials can be 
accessed (e.g. online appendix, URL). 
Examples: 
3a. “The educational package included a 12-minute cartoon…. The presentation of the 
cartoon was complemented by classroom discussions, display of the same poster that was 
used for the control group [Figure in web appendix 5], dissemination of a pamphlet 
summarising the key messages delivered in the cartoon, and drawing and essay-writing 
competitions to reinforce the messages. … The cartoon can be accessed at NEJM.org or at 
[URL provided]. A specific teacher training workshop was held before commencement of the 
trial (for details, see the protocol, available at NEJM.org).” 
3b. “The intervention group received a behaviour change counselling training programme 
called the Talking Lifestyle learning programme that took practitioners through a portfolio-
driven set of learning activities. Precise details of both intervention content and the training 
programme can be found in [URL, login and password provided]….. Box 1 provides a more 
detailed description of the components of the training programme.” 
3c. “The ‘local’ group received a sonographically guided injection of 2 ml (10 mg/ml) 
triamcinolone (Kenacort-T, Bristol-Myers Squibb) and 5 ml (10 mg/ml) lidocaine 
hydrochloride (Xylocaine, AstraZeneca) to the subacromial bursa and an intramuscular 
injection of 4 ml (10 mg/ml) lidocaine hydrochloride to the upper gluteal region.”    
Explanation: A full description of an intervention should describe what different physical and 
information materials were used as part of the intervention (this typically will not extend to study 
consent forms unless they provide written instructions about the intervention that are not 
provided elsewhere). Intervention materials are the most frequently missing element of 
intervention descriptions.3  This list of materials can be regarded as comparable to the 
‘ingredients’ required for a recipe. It may include materials provided to participants (example 3a) 
or training materials used with the intervention providers (examples 3a, 3b), or the surgical 
device or pharmaceutical drug used and its manufacturer (example 3c). For some interventions, it 
may be possible to describe the materials and the procedures (Item 4) together (examples 3c, 4c). 
If the materials are too long or complex to describe in the primary paper, alternative options and 
formats for providing the materials should be used (see web appendix 5  for some examples) and 
details of where they can be obtained (examples 3a, 3b) should be provided in the primary paper.  
Item 4. WHAT (procedures): Describe each of the procedures, activities, and/or processes 
used in the intervention, including any enabling or support activities. 
Examples: 
4a. “The TREPP [transrectus sheath preperitoneal] technique can be performed under spinal 
anaesthesia. To reach the PPS [preperitoneal space], a 5cm straight incision is made about 1cm 
above the pubic bone. The anterior rectus sheath is opened, as is the underlying fascia 
transversalis [Figure]. After retraction of the muscle fibres medially, the inferior epigastric vein 
and artery are identified and retracted medially as well.”  
4b. “…identified a suitable vein for cannulation. The overlying skin was wiped with an alcohol 
swab and allowed to dry, as per standard operating procedures. The principal investigator then 
administered the allocated spray from a distance of about 12 cm for two seconds. This 
technique avoided “frosting up” of vapocoolant on the skin. Liquid spray on the skin was 
allowed to evaporate for up to 10 seconds. The area was again wiped with an alcohol swab and 
cannulation proceeded immediately. Cannulation had to be carried out within 15 seconds of 
administration of the spray.” 
4c. “…three periods of exercise each lasting 5 min, supervised by a physiotherapist. The first 
period consisted of 2 min of indoor jogging, 1 min of stair climbing (three floors), and 2 min of 
cycling on an ergometer. Resistance on the ergometer was adjusted to ensure that the 
participant's respiratory rate was elevated during the 2 min of cycling. At the end of the first 
period, the patient performed several prolonged and brief expiratory flow accelerations with 
open glottis, the forced expiratory technique, and finally cough and sputum expectoration. 
These clearance manoeuvres were performed over 1.5 min. The second period consisted of 1 
min of stretching repeated five times, followed by the same expiratory manoeuvres for 1.5 min, 
as described above. The third period consisted of continuous jumping on a small trampoline. It 
included 2 min of jumping, 2 min of jumping while throwing and catching a ball, and 1 min of 
jumping while hitting a tossed ball. This was again followed by expiratory manoeuvres for 1.5 
min. The entire regimen was followed by 40 min rest.”                                                                                                                                                        
4d. “All health workers doing outpatient consultations in the intervention group received text 
messages about malaria case-management for 6 months. …The key messages addressed 
recommendations from the Kenyan national malaria guidelines and training manuals 
[references].”                                                                                                                          
4e. “Onsite activities were implemented by hospital personnel responsible for quality-
improvement initiatives…. Standard communication channels were used, including group-
specific, computer-based training modules and daily electronic documentation by nursing staff 
for all groups. On-site training in bathing with chlorhexidine-impregnated cloths was provided 
to hospitals assigned to a decolonisation regimen… Nursing directors performed at least three 
quarterly observations of bathing, including questioning staff about protocol details. 
Investigators hosted group-specific coaching teleconferences at least monthly to discuss 
implementation, compliance, and any new, potentially conflicting initiatives….” 
Explanation: Describe what processes, activities, or procedures the intervention provider/s 
carried out. Continuing the recipe metaphor used above, this item refers to the ‘methods’ section 
of a recipe and where intervention materials (‘ingredients’) are involved, describes what is to be 
done with them. ‘Procedure’ can refer to the sequence of steps to be followed (examples 3c, 4b) 
and is a term used by some disciplines, particularly surgery, and includes for example, pre-
operative assessment, optimisation, type of anaesthesia, peri-operative and post-operative care, 
along with details of the actual surgical procedure used (example 4a). Examples of processes or 
activities include referral, screening, case finding, assessment, education, treatment sessions 
(example 4c), telephone contacts (example 4d), etc. Some interventions, particularly complex 
ones, may require additional activities to enable or support the intervention to occur (in some 
disciplines these are known as implementation activities) and these should also be described 
(example 4e). Elaboration about how to report interventions where the procedure is not the same 
for all participants is provided at Item 9 (Tailoring).  
Item 5. WHO PROVIDED: For each category of intervention provider (e.g. psychologist, 
nursing assistant), describe their expertise, background and any specific training given. 
Examples: 
5a. “Only female counsellors were included in this rural area, after consultation with the village 
chiefs, because it would not have been deemed culturally appropriate for men to counsel 
women without their husband present… Selection criteria for lay counsellors included 
completion of 12 years of schooling, residence in the intervention area, and a history of 
community work.”  
5b. “The procedure is simple, uses existing surgical skills and has a short learning curve, with 
the manufacturers recommending at least 5 mentored cases before independently practising. 
All surgeons involved in the study will have completed this training and will have carried out 
over 5 procedures prior to recruiting to the study.”  
5c. “Therapists received at least 1 day of training specific to the trial from an experienced 
[cognitive behaviour therapy] CBT therapist and trainer and weekly supervision from skilled CBT 
supervisors at each centre…The intervention was delivered by 11 part-time therapists in the 
three sites who were representative of those working within NHS psychological services 
[reference]. Ten of the 11 therapists were female, their mean age was 39·2 years (SD 8.1), and 
they had practised as a therapist for a mean of 9·7 years (8·1). ...Nine of the 11 therapists 
delivered 97% of the intervention and, for these nine, the number of patients per therapist 
ranged from 13 (6%) to 41 (18%).”  
5d. “… brief lifestyle counselling was practised with trained actors and tape recorded. The 
competency of counselling was checked using the behaviour change counselling index 
[reference]. Only practitioners who reached a required standard (agreed by inter-rater 
consensus between three independent clinical assessors) were approved to deliver brief 
lifestyle counselling in the trial.”  
Explanation: The term “intervention provider” refers to who was involved in providing the 
intervention (for example, by delivering it to recipients or undertaking specific tasks). This is 
important in circumstances where the providers’ expertise and other characteristics (example 5a) 
could affect the outcomes of the intervention. Important issues to address in the description may 
include: the number of providers involved in delivering or undertaking the intervention; their 
disciplinary background (e.g. nurse, occupational therapist, colorectal surgeon, expert patient); 
what pre-existing specific skills, expertise, and experience providers required and if and how 
these were verified; details of any additional training specific to the intervention that needed to 
be given to providers before (example 3b) and/or during the study (example 5c); and if 
competence in delivering the intervention was assessed prior to (example 5d) or monitored 
throughout the study and whether those deemed lacking in competence were excluded (example 
5d) or retrained. Other information about providers may include: whether the providers were 
doing the intervention as part of their normal role (example 3b), or were specially recruited as 
providers for purposes of the study (example 5c); whether providers were reimbursed for their 
time or provided with other incentives (if so, what) to deliver the intervention as part of the study, 
and whether such time or incentives may be needed to replicate the intervention.  
Item 6. HOW: Describe the modes of delivery (e.g. face-to-face or by some other mechanism, 
such as internet or telephone) of the intervention and whether it was provided individually or 
in a group. 
Examples: 
6a. “…sessions … held weekly and facilitated in groups of 6–12 by…” 
6b. “Drugs were delivered by … members of the [Reproductive and Child Health] trekking 
teams… teams visited each of the study villages…” 
6c.  “The text messaging intervention, SMS Turkey, provided 6 weeks of daily messages aimed 
at giving participants skills to help them quit smoking. Messages were sent in an automated 
fashion, except 2 days and 7 days after the initial quit day”. 
6d. “…made their own appointments online. …Participants and therapists typed free text into 
the computer, with messages sent instantaneously; no other media or means of 
communication were used.”  
6e. “…3 1-hour home visits (televisits) by a trained assistant…; participants' daily use of an in-
home messaging device … that was monitored weekly by the teletherapist; and 5 telephone 
intervention calls between the teletherapist and the participant….” 
Explanation: Specify whether the intervention was provided to one participant at a time (such as 
a surgical intervention) or to a group of participants and if so, the group size (example 6a). Also 
describe whether it was delivered face-to-face (example 6b), by distance (such as by telephone, 
surface mail, email, internet, DVD, mass media campaign, etc) as in examples 6c, 6d, or a 
combination of modes (example 6e). Where relevant, describe who initiated the contact (example 
6c), and whether the session was interactive (example 6d) or not (example 6c), and any other 
delivery features considered essential or likely to influence outcome.  
Item 7. WHERE: Describe the type(s) of location(s) where the intervention occurred, 
including any necessary infrastructure or relevant features. 
Examples: 
7a. “…medication… and a spacer (as appropriate) were delivered to the school nurse for directly 
observed therapy on the days on which the child attended school… An additional canister of 
preventive medication was delivered to the child’s home to use on weekends and other days 
the child did not attend school, and the child’s caregiver was shown proper administration 
technique.” 
7b. “Women were recruited from three rural and one peri-urban antenatal clinic in Southern 
Malawi……tablets were taken under supervision at the clinic.” 
7c. “…participants for the …telehealth trial, across three sociodemographically distinct regions 
in England (rural Cornwall, rural and urban Kent, and urban Newham in London) comprising 
four primary care trusts… Control participants had no telehealth or telecare equipment 
installed their homes for the duration of the study. A Lifeline pendant (a personal alarm) plus a 
smoke alarm linked to a monitoring centre were not, on their own, sufficient to classify as 
telecare for current purposes.” 
7d. “Most births in African countries occur at home, especially in rural areas… They identified 
pregnant women and made five home visits during and after pregnancy…Peer counsellors lived 
in the same communities, so informal contacts to make arrangements for visits were common. 
…counsellors were … given a bicycle, T-shirt,…” 
7e. This paper contains a Box, titled “Key features of healthcare systems in Northern Ireland 
and Republic of Ireland” which summarises relevant aspects of general practices such as 
funding, registration, and access to free prescriptions.  
Explanation: In some studies the intervention may be delivered in the same location where 
participants were recruited and/or data were collected and details may therefore already be 
included in the primary paper (e.g. as in Item 4b of CONSORT 2010 statement if reporting a 
trial). If however, the intervention occurred in different locations, this should be specified. At its 
simplest level, the location might be, for example, in the participants’ home (example 7a), 
residential aged care facility, school (example 7a), outpatient clinic (example 7b), inpatient 
hospital room, or a combination of locations (example 7a). Features or circumstances about the 
location may be relevant to the delivery of the intervention and should be described (examples 
7e). For example, they might include the country (example 7b), type of hospital or primary care 
(example 7c), publicly or privately-funded care, volume of activity, details of the health care 
system, or the availability of certain facilities or equipment (examples 7c,7d, 7e). These features 
may impact on various aspects of the intervention such as its feasibility (example 7d) or provider 
or participant adherence and are important for those considering replicating the intervention to be 
aware of.  
Item 8. WHEN and HOW MUCH: Describe the number of times the intervention was 
delivered and over what period of time including the number of sessions, their schedule, and 
their duration, intensity or dose. 
Examples: 
8a. “a loading dose of 1 g of tranexamic acid infused over 10 min, followed by an intravenous 
infusion of 1 g over 8 h…” 
8b. “They received five text messages a day for the first 5 weeks and then three a week for the 
next 26 weeks.” 
8c. “…exercise 3 times a week for 24 weeks… Participants began with 15 minutes of exercise 
and increased to 40 minutes by week 8…. Between weeks 8 and 24, attempts to increase 
exercise intensity were made at least weekly either by increasing treadmill speed or by 
increasing the treadmill grade. Participants with leg symptoms were encouraged to exercise to 
near maximal leg symptoms. Asymptomatic participants were encouraged to exercise to a level 
of 12 to 14 …on the Borg rating of perceived exertion scale [reference].”  
8d. “… delivered weekly one hour sessions in the woman’s home, for up to 8 weeks,... starting 
at around 8 weeks postnatally.”  
Explanation: The type of information needed about the ‘when and how much’ of the 
intervention will differ according to the type of intervention. For some interventions some 
aspects will be more important than others. For example, for pharmacological interventions, the 
dose and scheduling is often important (example 8a); for many non-pharmacological 
interventions, the ‘how much’ of the intervention is instead described by the duration and 
number of sessions (examples 8b, 8c). For multiple-session interventions, the schedule of the 
sessions is also needed (example 8b) and if the number of sessions, their schedule, and/or 
intensity was fixed (examples 8b, 4c, 6a) or if it could be varied according to rules and if so, 
what they were (example 8c). Tailoring of the intervention to individuals or groups of 
individuals is elaborated on in Item 9 (Tailoring). For some interventions, as part of the ‘when’ 
information, detail about the timing of the intervention in relation to relevant events may also be 
important (for example, how long after diagnosis, first symptoms, or a crucial event did the 
intervention commence) (example 8d). As described below in Item 12, the “amount” or dosage 
of intervention that participants actually received may differ from the amount intended. This 
detail should be described, usually in the Results section (examples 12a-c).  
Item 9. TAILORING: If the intervention was planned to be personalised, titrated or adapted, 
then describe what, why, when, and how 
Examples: 
9a. “Those allocated to the intervention arm followed an intensive stepped programme of 
management, with mandatory visits to their doctor at weeks 6, 10, 14, and 18 after 
randomisation to review their blood pressure and to adjust their treatment if needed according 
to prespecified algorithms [provided in supplementary appendix].” 
9b. “All patients received laparoscopic mini-gastric bypass surgery… The bypass limb was 
adjusted according to the preoperative BMI [Body Mass Index] of the patient. A 150cm limb 
was used for BMI 35, with a 10cm increase in the bypass limb with every BMI category increase, 
instead of using a fixed limb for all patients.” 
9c. “Participants began exercising at 50% of their 1 rm [repetition maximum]. Weights were 
increased over the first 5 weeks until participants were lifting 80% of their 1 rm. Weights were 
adjusted after each monthly 1 rm and as needed to achieve an exercise intensity of a rating of 
 
perceived exertion of 12 to 14.”   
9d. “Stepped-care decisions for patients … were guided by responses to the 9-item Patient 
Health Questionnaire [reference], administered at each treatment visit and formally evaluated 
at 8-week intervals. Patients who did not show prespecified improvement were offered the 
choice of switching treatments (eg, from Problem Solving Therapy to medication), adding the 
other treatment, or intensifying the original treatment choice, based on the treatment team's 
recommendation (for details, see [reference])”. 
Explanation: In tailored interventions, not all participants receive an identical intervention. 
Interventions may be tailored for several reasons, such as titration to obtain an appropriate 
“dose” (example 9a); participant preference, skills or situation (example 9b); or it may be an 
intrinsic element of the intervention as with increasing intensity of an exercise (example 9c). 
Hence, a brief rationale and guide for tailoring should be provided, including any 
variables/constructs used for participant assessment (examples 9b, 9c) and subsequent tailoring. 
Tailoring may occur at several stages and authors should describe any decision points and rules 
used at each point (example 9d). If any decisional or instructional materials are used, such as 
flowcharts, algorithms or dosing-nomograms, these should be included, referenced (example 9d), 
or their location provided (example 9a). 
Item 10. MODIFICATIONS: If the intervention was modified during the course of the study, 
describe the changes (what, why, when, and how). 
Examples:  
10a. “A mixture of general practitioners and practice care nurses delivered 95% of screening 
and brief intervention activity in this trial….Owing to this slow recruitment, research staff who 
had delivered training in study procedures supported screening and brief intervention delivery 
in 10 practices and recruited 152 patients, which was 5% of the total number of trial 
participants”  
10b. “Computers with slow processing units and poor internet connections meant that seven 
general practitioners never got functional software; they used a structured paper version that 
was faxed between the research team and general practitioner after each appointment…”  
Explanation: This item refers to modifications that occur at the study level, not individual 
tailoring as described in Item 9. Unforseen modifications to the intervention may occur during 
the course of the study, particularly in early studies. If this happens it is important to explain 
what was modified, why and when modifications/s occurred, and how the modified intervention 
differed from the original (example 10a - modification to who provided the intervention; 
example 10b - modification in the materials). Modifications sometimes reflect changing 
circumstances. In other studies, they can demonstrate learning about the intervention which is 
important to transmit to the reader and others to prevent unnecessary repetition of errors during 
attempts to replicate the intervention. If changes to the intervention occurred between the 
published protocol or published pilot study and the primary paper, these changes should also be 
described. 
Item 11. HOW WELL (planned): If intervention adherence or fidelity was assessed, describe 
how and by whom, and if any strategies were used to maintain or improve fidelity, describe 
them. 
Examples: 
11a. “Pathologists were trained to identify lateral spread of tumour according to the protocol … 
[reference]. The results of histopathological examination of the specimens were reviewed by a 
panel of supervising pathologists and a quality manager.” 
11b. “…Staff in the study sites were trained initially, and therapy supervision was provided by 
weekly meetings between therapists and investigators. Cognitive therapy sessions were taped 
with the participant’s consent so that participants could be asked to listen to the tapes as part 
of their homework and to assist supervision. During the course of the trial a sample of 80 tapes 
was rated according to the cognitive therapy scale-revised [reference] and the cognitive 
therapy for at risk populations adherence scale [reference] to ensure rigorous adherence to the 
protocol throughout the duration of the trial. These tapes were drawn from both early and late 
phases of therapy and included participants from each year of recruitment.” 
11c. “Adherence to trial medication was assessed by means of self-reported pill counts 
collected during follow-up telephone calls. These data were categorised as no pills taken, hardly 
any taken (1 to 24% of prescribed doses), some taken (25 to 49%), most taken (50 to 74%), or 
all taken (75 to 100%).” 
11d. “Training will be delivered independently in each of the three regional study centres. All 
trainers will adhere to a single training protocol to ensure standardised delivery of the training 
across centres. Training delivery will be planned and rehearsed jointly by all trainers using role-
play and peer review techniques. In addition, the project manager will act as an observer during 
the first two training sessions in each centre and will provide feedback to trainers with a view to 
further standardising the training.” [example from a protocol] 
Explanation: Fidelity refers to the degree to which an intervention happened in the way the 
investigators intended it to20 and can affect the success of an intervention.21  The terms used to 
describe this concept vary among disciplines and include treatment integrity, provider or 
participant adherence, and implementation fidelity. This item – and Item 12 - extends beyond 
simple receipt of the intervention (such as how many participants were issued with the 
intervention medication or exercises), but refers to ‘how well’ the intervention was received or 
delivered (such as how many participants took the medication/did the exercises, how much they 
took/did, and for how long). Depending on the intervention, fidelity may apply to one or more 
areas of the intervention, such as training of providers (examples 11a, 11b, 11d), delivery of the 
intervention (example 11b), and receipt of the intervention (example 11c). The types of measures 
used to determine intervention fidelity will also vary according to the type of intervention. For 
example, in simple pharmacological interventions, assessing fidelity often focusses on recipient 
adherence to taking the medication (example 11b). However, in complex interventions, such as 
rehabilitation, psychological or behaviour change interventions, assessment of fidelity is also 
more complex (example 11b). There are various pre-planned strategies and tools that can be used 
to maintain fidelity, before delivery of the intervention (example 11d) or during the study 
(example 11b). If any strategies or tools were used to maintain fidelity, they should be clearly 
described. Any materials used as part of assessing or maintaining fidelity should be included, 
referenced, or their location provided.  
Item 12: HOW WELL (actual): If intervention adherence or fidelity was assessed, describe the 
extent to which the intervention was delivered as planned. 
Examples:   
12a.   “…The mean (SD) number of physiotherapy sessions attended was 7.5 (1.9). Seven 
patients (9%) completed less than 4 physiotherapy sessions; the reasons included 
nonattendance, moving interstate, or recovery from pain. Of patients in the physiotherapy 
groups, 70% were compliant with their home exercise program during at least 5 of 7 weeks.” 
12b. “The [early exercise] EE group reported an adherence rate of 73% at [time] T2 and 75.7% 
at [time] T3, and the [delayed exercise] CE group reported 86.7% adherence at T3. …with the 
early exercise EE group reporting disease and treatment-related barriers to exercise during 
their cancer treatment (“week of chemotherapy” 14%; “fatigue” 10%); or life-related barriers 
(“illness e.g., colds or flu” 16%; “family obligations” 13%).” 
12c. “A total of 214 participants (78%) reported taking at least 75% of the study tablets; the 
proportion of patients who reported taking at least 75% of the tablets was similar in the two 
groups…” 
12d. “The integrity of the psychological therapy was assessed with the cognitive therapy rating 
scale [reference] to score transcripts of 40 online sessions for patients who had completed at 
least five sessions of therapy. With use of computer-generated random numbers, at least one 
such patient was selected for each therapist. For these patients, either session 6 or the 
penultimate session was rated by two independent CBT [cognitive-behaviour therapy]-trained 
psychologists, who gave mean ratings of 31 (SD between therapists 9) and 32 (13) of 72.”  
Explanation: For various reasons, an intervention, or parts of it, may not be delivered as intended, 
thus affecting the fidelity of the intervention. If assessed, authors should describe the extent to 
which the delivered intervention varied from the intended intervention. This information may 
help to explain study findings, minimise errors in interpreting study outcomes, inform future 
modifications to the intervention, and where fidelity is poor, may point to the need for further 
studies or strategies to improve fidelity or adherence. 22,23 For example, there may be some 
aspects of the intervention that participants do not like and this may influence their adherence. 
The way in which the intervention fidelity is reported will reflect the measures used to assess it 
(examples 12a-d), as described in Item 11.  
Discussion 
We describe a short list of items that we believe can be used to improve the reporting of 
interventions and make it easier for authors to structure accounts of their interventions, reviewers 
and editors to assess the descriptions, and readers to use the information. Consistent with the 
CONSORT 2010 and SPIRIT 2013 statements, we recommend that interventions are described 
in enough detail to enable replication, and recommend authors use the TIDieR checklist to 
achieve this. As including all intervention details is not always be possible in the primary paper 
of a study, the TIDieR checklist encourages authors to indicate that they have reported each of 
the items and to also state where this information is located (see Table 1 and web appendix 3). 
The number of checklist items reported is improved when journals require checklist completion 
as part of the submission process.24 We encourage journals to endorse the use of the TIDieR 
checklist, in a similar way to CONSORT and related statements. This may be done by modifying 
their author instructions, publishing an editorial about intervention reporting, and including a link 
to the checklist on their website. Very few journals currently provide specific guidance about 
how to report interventions.25 A small number have editorial policies stating they will not publish 
trials unless intervention protocols or full details are available.26 We encourage other journals to 
consider adopting similar policies. Any links provided by journals and authors should be reliable 
and enduring. Stable depositories for intervention descriptions are also required and their 
development needs the contribution and collaboration of all research community stakeholders 
(e.g. researchers, journal editors, publishers, research funding bodies). 
For authors submitting reports of randomised trials, we suggest using TIDieR in conjunction 
with the CONSORT checklist: when completing Item 5 of the CONSORT checklist, insert “refer 
to TIDieR checklist” and provide a separate, completed TIDieR checklist. For journals that adopt 
this recommendation, their instructions to authors will need to be modified accordingly and their 
editors and reviewers made aware of the change. Similarly, for authors submitting protocols of 
trials, the TIDieR checklist can be referred to when addressing Item 11 of the SPIRIT 2013 
checklist. One point of difference is that two TIDieR items (Items 10 and 12) are not applicable 
to intervention reporting in protocols because they cannot be completed until the study is 
complete. This is noted on the TIDieR checklist. Published protocols are likely to grow in 
importance as a source of information about the intervention and using TIDieR in conjunction 
with the SPIRIT 2013 Statement may facilitate this. For authors of study designs other than 
randomised trials, TIDieR may be used alone as a standalone checklist or in conjunction with the 
relevant statement for that study design (e.g. STROBE Statement12). We acknowledge that 
describing complex interventions well can be challenging and that for some particularly complex 
interventions, a checklist, such as TIDieR, may go some way towards assisting with intervention 
reporting but may not be able to capture the full complexity of these interventions.   
We recognise that adhering to the TIDieR checklist may increase the word count of a paper, 
particular if the study protocol is not publicly available. We believe this may be necessary to 
help improve the reporting of studies generally and interventions specifically. As journals 
recognise the importance of well reported studies and fully described methods, and many move 
to a model of online-only, or a hybrid of printed and online with posting of the full study 
protocol, this may become less of a barrier to quality reporting. For example, the Nature 
Publishing Group recently removed word limits on the Methods section of submitted papers and 
advises that: “If more space is required to describe the methods completely, the author should 
include the 300-word section ‘Methods Summary’ and provide an additional ‘Methods’ section 
at the end of the text, following the figure legends. This Methods section will appear in the 
online… version of the paper, but will not appear in the printed issue. The Methods section 
should be written as concisely as possible but should contain all elements necessary to allow 
interpretation and replication of the results.” 27 
Systematic reviewers may also wish to be guided by the TIDieR items when describing 
interventions in systematic reviews so that readers of reviews have access to full details of any 
intervention (or at least details about where to obtain further information) which they wish to 
replicate after reading the review.  
The TIDieR checklist and guide should assist authors, editors, peer reviews, and readers. Some 
authors might perceive this checklist as another time consuming hurdle and elect to seek 
publication in a journal that does not endorse reporting guidelines. There is a very large evidence 
base indicating that the quality of reporting of health research is unacceptably poor. Properly 
endorsed and implemented reporting guidelines offer a way for publishers, editors, peer 
reviewers, and authors to do a better job of completely and transparently describing what was 
done and found.28 Doing so will help reduce wasteful research 29,30 and increase the potential 
impact of research on health.  
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